Papillomavírus jab. A Human Papillomavirus vaccine keresési eredményei - Klinikai vizsgálatok nyilvántartása - ICH GCP

University of Pittsburgh Rövid összefoglaló This is a randomized, open label trial of HPV human papilloma virus vaccine, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule.

They would be randomized to either vaccine at 6 months or vaccine at 12 months. Blood will be drawn for titers twice from all participants: pre-dose 1 and one month post third dose.

Részletes leírás The recommendations for HPV vaccine include catch-up of women 18 to 26 years old. Given that a large percentage of women in this age group are attending college, a good place to access them would be through the student health services on college campuses.

However, papillomavírus jab HPV vaccine schedule papillomavírus jab 0, 2, and 6 months is likely to be papillomavírus jab to implement in a college calendar year and the immunogenicity of alternative schedules is unknown.

If the immunogenicity of an altered schedule is good, then higher vaccination rates may be achievable. Aims: 1. Determine if delay in the third dose is immunologically non-inferior to the standard administration schedule 1 month post-dose 3.

Determine the side effect profile of a delayed third dose, in comparison to the standard schedule Átfogó állapot.